

**Client:** 

Test:

**Report Date:** 

Report No.:	TR 066-051A
Date:	July 22, 2024
Page :	1

**Receipt Date:** 7/19/2024 **Analysis Date:** 7/22/2024

### Matrix: Powder

Number of samples: 1

# Certificate of Analysis

## **Purity: 99.4%**

20240722_SMPL_BPC157_TB4_LotBPCTHYE124_Purit y.d	Sample Name	BPC-157 + TB4 lot BPCTHYE124
Sample	Position	P2-F4
Instrument 1	User Name	
PuritydefaultMS2.m	Acquired Time	7/22/2024 3:10:43 PM (UTC-07:00)
Not Applicable	DA Method	20211216_PIS7_165and211_quad_SCAN_POS_Nowar taDSDPRWV_neat.m
	Info.	
LC 1	Acquisition Time (Local)	7/22/2024 3:10:43 PM (UTC-07:00)
6400 Series Triple Quadrupole B.09.00 (B9037.0)		
	y.d Sample Instrument 1 PuritydefaultMS2.m Not Applicable	y.d L L L L L Sample Name Sample Position Instrument 1 User Name PuritydefaultMS2.m Acquired Time Not Applicable D A Method LC 1 Acquisition Time (Local)

Sovereign Health and Performance


Sample Name: BPC-157 (1mg) + TB-4 (10mg)


7/22/2024

Purity

Batch#: BPCTHYE124

#### Chromatograms





### Peak List

Time	Area	%Area
4.323 min.	28.47	0.6%
5.282 min.*	3700.28	74.3%
5.422 min.**	1248.55	25.1%
Combined		
purity:		99.4%

\* determined as TB-4 based on retention time

\*\* determined as BPC-157 based on retention time

Note-percent area between compounds is not quantitative due to variable extinction coefficients

Reviewed and Approved By:

Herman Lelie

Constitution Labs (CL) maintains liability limited to cost of analysis. Interpretation and use of test results are the responsibility of the client. This report relates only to the samples reported above, and may not be reproduced, except in full, without written approval by CL. This is not intended as an endorsement of any product. CL bears no responsibility for sample collection activities or analytical method limitations. Samples are within quality control criteria and met method specifications unless otherwise noted.